Innate Pharma Share and Voting Rights Update: July 3, 2025

MARSEILLE, France–(BUSINESS WIRE)–
Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq:
IPHA
) (“Innate” or the “Company”) today announced its total number of outstanding shares and voting rights as of July 3, 2025, in compliance with French regulatory requirements, specifically Article L. 233-8 II of the French “Code de Commerce” and Article 223-16 of the French stock-market authorities’ General Regulation.

(1) The total number of theoretical voting rights, also referred to as “gross” voting rights, serves as the benchmark for calculating shareholding threshold crossings. This figure includes all shares with attached voting rights, even those where voting rights are suspended, as per Article 223-11 of the AMF General Regulation. Specifically, it incorporates voting rights attached to AGAP 2016, totaling 130 for AGAP 2016-1 and 111 for AGAP 2016-2. Notably, no voting rights are attached to AGAP 2017.

(2) The total number of exercisable voting rights, or “net” voting rights, excludes shares held in treasury by the Company and those with suspended voting rights. This disclosure is made to ensure comprehensive market information, aligning with the AMF’s recommendation of July 17, 2007.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company’s pioneering strategy focuses on harnessing the power of the innate immune system through three distinct therapeutic avenues: multi-specific NK Cell Engagers leveraging its proprietary ANKET^® (Antibody-based NK cell Engager Therapeutics) platform, Antibody Drug Conjugates (ADCs), and monoclonal antibodies (mAbs).

The company’s robust pipeline features several ANKET^® drug candidates targeting a range of tumor types, alongside IPH4502, a differentiated ADC currently in development for solid tumors. Additionally, Innate Pharma is advancing anti-KIR3DL2 mAb lacutamab for advanced cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and anti-NKG2A mAb monalizumab in collaboration with AstraZeneca for non-small cell lung cancer.

Innate Pharma is recognized as a preferred partner by leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as esteemed research institutions, demonstrating its commitment to accelerating innovation and research for the ultimate benefit of patients.

Headquartered in Marseille, France, with a US presence in Rockville, MD, Innate Pharma is publicly traded on both Euronext Paris and the Nasdaq in the United States.

Discover more about Innate Pharma at
www.innate-pharma.com
and follow our progress on
LinkedIn
and
X
.

Innate Pharma Share Information

Forward-Looking Information and Risk Factors Disclaimer

This press release contains forward-looking statements, as defined under applicable securities laws, including the Private Securities Litigation Reform Act of 1995. These statements, often identifiable by terms such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or their negatives and similar expressions, are subject to numerous risks and uncertainties. While the Company believes its expectations are grounded in reasonable assumptions, actual results may differ materially from those projected. Key risks and uncertainties include, but are not limited to, those inherent in research and development, including the safety, progression, and outcomes of ongoing and planned clinical trials and preclinical studies. Regulatory review and approval processes for its product candidates, reliance on third-party manufacturers, commercialization efforts, and the Company’s ability to secure ongoing funding for its development programs are also critical factors. A more detailed discussion of these risks and uncertainties, which could cause the Company’s actual results, financial condition, performance, or achievements to deviate from forward-looking statements, can be found in the “Risk Factors” section of the Company’s Universal Registration Document filed with the French Financial Markets Authority (“AMF”), accessible on the AMF website at
http://www.amf-france.org
, and on Innate Pharma’s website. Investors should also consult public filings and reports submitted to the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the AMF or SEC. The content of the Company’s and the AMF’s websites is provided for informational purposes only and is not incorporated by reference into this press release.

Given the inherent uncertainties in these forward-looking statements, readers are cautioned against placing undue reliance on them as representations or warranties of future achievement of the Company’s objectives and plans. Innate Pharma undertakes no obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise, except as required by law.

This press release and its contents do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for Innate Pharma shares in any jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250703076027/en/